Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
As previously reported, TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with an $8 price target after Cardamyst nasal spray was approved by the FDA for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. The label is clean with no market-limiting warnings or monitoring requirements, notes the analyst, who also points out that Cardamyst will be available in retail pharmacies in Q1 of 2026 with a wholesale acquisition cost of $1,649.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
Disclaimer & DisclosureReport an Issue
- Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen
- Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential
- Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
- Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST
- Milestone Pharmaceuticals receives FDA approval of CARDAMYST
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.